Skip to main content

Susvimo FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 27, 2021.

FDA Approved: Yes (First approved October 25, 2021)
Brand name: Susvimo
Generic name: ranibizumab
Dosage form: Injection for Intravitreal Use via Ocular Implant
Company: Genentech, Inc.

Susvimo (ranibizumab) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.

Development timeline for Susvimo

DateArticle
Jul  8, 2024Genentech to Reintroduce Susvimo for People With Wet Age-Related Macular Degeneration (AMD)
Oct 22, 2021Approval FDA Approves Susvimo (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration (AMD)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.